INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
March 26 2024 - 4:01PM
INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage
immunology and inflammation company focused on developing
treatments that harness a patient’s innate immune system to fight
disease, today announced that it will host a conference call on
Thursday, March 28, 2024 at 4:30 PM Eastern Time to discuss results
for its fourth quarter ended December 31, 2023 and to provide a
corporate update.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes
before the beginning of the call. Please ask for the INmune Bio
Fourth Quarter Conference Call when reaching an operator.
Date: March 28, 2024 Time: 4:30 PM Eastern Time Participant
Dial-in: 1-877-407-0784 Participant Dial-in (international):
1-201-689-8560 Conference ID: 13744427
A live audio webcast of the call can be accessed by
clicking here or using this link:
https://callme.viavid.com/viavid/?callme=true&passcode=13739436&h=true&info=company&r=true&B=6
A transcript will follow approximately 24 hours from the
scheduled call. A replay will also be available through April 3 by
dialing 1-844-512-2921 or 1-412-317-6671 (international) and
entering PIN no. 13744427.
About INmune Bio Inc.
INmune Bio, Inc. is a publicly traded
(NASDAQ: INMB), clinical-stage biotechnology company focused on
developing treatments that target the innate immune system to fight
disease. INmune Bio has two product platforms that are both in
clinical trials: The Dominant-Negative Tumor Necrosis Factor
(DN-TNF) product platform utilizes dominant-negative technology to
selectively neutralize soluble TNF, a key driver of innate immune
dysfunction and a mechanistic driver of many diseases. XPRO, the
first of several DN-TNF products, is in clinical trials to
determine if it can treat patients with Mild Alzheimer’s disease.
Additional therapeutic indications including d treatment-resistant
depression and oncology will be pursued when resources allow. The
Natural Killer Cell Priming Platform includes INKmune™, a therapy
developed to prime a patient’s NK cells to treat patients with
cancer. INKmune uses a precision medicine approach for the
treatment of a wide variety of hematologic and solid tumor
malignancies. The INKmune trial is enrolling patients into a US
Phase I/II trial in men with metastatic castrate resistant prostate
cancer. To learn more, please
visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in the early stages and there is no
assurance that any specific outcome will be achieved. Any
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995. Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties, including, without limitation,
uncertainties related to market conditions, the completion of the
public offering on the anticipated terms or at all and the
Company’s intention to grant the underwriters an option to purchase
additional shares. INB03™, XPro™, and INKmune™ are still in
clinical trials or preparing to start clinical trials and have not
been approved by the US Food and Drug Administration (FDA) or any
regulatory body and there cannot be any assurance that they will be
approved by the FDA or any regulatory body or that any specific
results will be achieved. The factors that could cause actual
future results to differ materially from current expectations
include, but are not limited to, risks and uncertainties relating
to the Company’s ability to produce more drug for clinical trials;
the availability of substantial additional funding for the Company
to continue its operations and to conduct research and development,
clinical studies and future product commercialization; and, the
Company’s business, research, product development, regulatory
approval, marketing and distribution plans and strategies. These
and other factors are identified and described in more detail in
the Company’s filings with the Securities and Exchange Commission,
including the Company’s Annual Report on Form 10-K, the Company’s
Quarterly Reports on Form 10-Q and the Company’s Current Reports on
Form 8-K. The Company assumes no obligation to update any
forward-looking statements in order to reflect any event or
circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO (858) 964-3720
info@inmunebio.com
Investor Contact:
Jason Nelson Core IR (516) 842-9614 x-823
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Apr 2024 to May 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From May 2023 to May 2024